Novel strategy provides new hope to fight COVID-19

A novel strategy has been developed by Novateur Ventures, which provides new hope in battle against COVID-19. The study titled ‘A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes’ was published in Frontiers in Pharmacology, a leading peer-reviewed journal.

The strategy co-authored by Ali Ardakani, Founder & Managing Director at Novateur Ventures, and Dr. Colin D. Funk (Queen’s University, Kingston) analyzes lipid mediators, known as leukotrienes, as the cause for hyperinflammatory response manifested in severe COVID-19 cases.

Patients with severe COVID-19 develop an overwhelming state of inflammation with multi-organ dysfunction and leukotrienes have been overlooked.

Globally the race to develop new therapeutics or repurpose existing drugs to cultivate an effective therapeutic treatment for COVID- 19 is urgent. At Novateur, our research has been well underway since the first cases were discovered. I am very pleased today to announce a strategy we believe can potentially impact COVID-19 patients in a safe and effective manner.”

Ali Ardakani, Founder & Managing Director at Novateur Ventures

Since Novateur began their in-depth studies, only two treatments (remdesivir, dexamethasone) have demonstrated modest ability to reduce disease progression and severity; however, there is still a high unmet need for additional improvement. Leukotrienes have some of the most potent impacts on immune cell trafficking and vascular leakage in biological systems, two important steps that take place in COVID-19.

Novateur’s research proposes a simple treatment paradigm using two generic drugs, normally directed to blocking inflammation in airways of patients with asthma, to target the hyper-inflammatory response insevere COVID-19.

تواصل مع فريق المدونة


6 + 14 =